{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
acetylcysteine
to a specific field?
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control phenylalanine
Source URL:
First approved in 1971
Source:
NDA016822
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Phenylalanine is a biologically essential amino acid that acts as a precursor to tyrosine and the catecholamines (epinephrine, norepinephrine, dopamine, and tyramine), and is a constituent
of many central nervous system neuropeptides. Normal dietary levels of phenylalanine are approximately 1-2 grams daily. Phenylalanine appears in two forms which are identical mirror images of each other: L-phenylalanine, a nutritional supplement, and D-phenylalanine, an effective painkiller and antidepressant due to its ability to inhibit the breakdown of enkephalins, the brain’s natural pain killers.
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control lysine hydrochloride
Source URL:
First approved in 1971
Source:
NDA016822
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.
Status:
Possibly Marketed Outside US
Source:
NCT03822637: Phase 4 Interventional Terminated Asthma
(2019)
Source URL:
First approved in 2019
Source:
ULTRA HIS MINT by CROWN GENERAL AGENCY INC
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
N-monoacetylcystine is monoacetylated derivative of L-cystine, a covalently linked dimeric nonessential aminoacid formed by the oxidation of cysteine. N-monoacetylcystine is accumulated in the plasma of uraemic patients.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Thiamphenicol aminoacetate is an antibiotic. It is the methyl-sulfonyl analogue of chloramphenicol and has a similar spectrum of activity, but is 2.5 to 5 times as potent. It is used in many countries as a veterinary antibiotic, but is available in China, Morocco and Italy for use in humans. Thiamphenicol aminoacetate is reported as an ingredient of Urfamycin in Ecuador, Indonesia, Italy, Taiwan, Thailand, Turkey, Japan. It is indicated for the treatment of GUT, hepatobiliary, respiratory tract, enteric tract infections, typhoid, paratyphoid fever and salmonellosis, brucellosis.
Status:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Acetylcysteine amide (NACA) is a novel thiol-containing antioxidant. NACA is a modified form of its parent compound N-acetylcysteine (NAC) that is a precursor of the most abundant endogenous antioxidant, glutathione (GSH). NACA demonstrated the multiple therapeutic abilities, including antioxidant, anti-apoptotic, and anti-inflammatory properties with greater efficacy compared to its parent compound. NACA treatment significantly maintained acute mitochondrial bioenergetics and normalized GSH levels following spinal cord injury. It is a new neuroprotective drug, that might be effective at slowing down nigral neuronal degeneration and illness progression in patients with Parkinson's disease.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
First approved in 1962
Class:
MIXTURE
Status:
US Approved Rx
(1993)
Source:
BLA103532
(1993)
Source URL:
First approved in 1993
Source:
BLA103532
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:certepetide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001296: Phase 3 Interventional Completed Melanoma
(1992)
Source URL:
Class:
PROTEIN
